The current status of malaria vaccines

BioDrugs

Volumn 10, Issue 2, 1998, Pages 123-136

  Stoute, José A ^a   Ballou, W Ripley ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; MALARIA VACCINE; PLASMID DNA; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; SPOROZOITE VACCINE; VIRUS VECTOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; HUMAN; LIFE CYCLE; MALARIA FALCIPARUM; MEROZOITE; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SPOROZOITE; VACCINATION; VACCINE PRODUCTION; VIRUS ATTENUATION;

EID: 0031694328     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810020-00004     Document Type: Review

References (113)

1. Dame JB, Williams JL, McCutchan TF, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984 Aug 10; 225 (4662): 593-9
2. Enea V, Ellis J, Zavala F, et al. DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 1984 Aug 10; 225 (4662): 628-30
3. Caspers P, Gentz R, Matile H, et al. The circumsporozoite gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials. Mol Biochem Parasitol 1989; 35: 185-9
4. Burkot TR, Da ZW, Geysen HM, et al. Fine specificities of monoclonal antibodies against the Plasmodium falciparum circumsporozoite protein: recognition of both repetitive and nonrepetitive regions. Parasite Immunol 1991; 13: 161-70
5. Potocnjak P, Yoshida N, Nussezweig R, et al. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 1980 Jun; 151: 1504-13
6. Yoshida N, Nussezweig RS, Potocnjak P, et al. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 1980; 207: 71
7. Ballou WR, Sherwood JA, Neva FA, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987 Jun 6; 1277-81
8. Herrington DA, Clyde DF, Losonsky G, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987 Jul 16; 328: 257-9
9. Fries LF, Gordon DM, Schneider I, et al. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun 1992 May; 60 (5): 1834-9
10. Ribi E, Cantrell J, Feldner T, et al. Biological activities of monophosphoryl lipid A. In: Levine L, Bonventre PF, Morello JA, et al., editors. Microbiology. Washington, DC: American Society for Microbiology, 1986
11. Fries LF, Gordon DM, Richards RL, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992 Jan; 89: 358-62
12. Hoffman SL, Edelman R, Bryan JP, et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalene as adjuvant. Am J Trop Med Hyg 1994; 51 (5): 603-12
13. Weiss WR, Sedegah M, Beaudoin R, et al. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 1987 Jan; 85: 573-6
14. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987 Dec; 330: 664-6
15. Sinigaglia F, Matile H, Pink JRL. Plasmadium falciparum-specific human T cell clones: evidence for helper and cytotoxic activities. Eur J Immunol 1987; 17: 187-92
16. Good MF, Pombo D, Quakyi IA, et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1988 Feb; 85: 1199-203
17. Kumar S, Miller LH, Quakyi IA, et al. Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature 1988 Jul; 334: 258-60
18. Sinigaglia F, Guttinger M, Kilgus J, et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988 Dec; 336: 778-80
19. + T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 1993 Jul; 151: 489-99
20. Malik A, Egan JE, Houghten RA, et al. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 1991 Apr 15; 88 (8): 3300-4
21. Cerami C, Frevert U, Sinnis P, et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 1992 Sep; 70: 1021-33
22. Heppner DG, Gordon DM, Gross M, et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 1996; 174: 361-6
23. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995; 171: 1576-85
24. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997; 336: 86-91
25. Vreden SGS, Verhave JP, Oettinger T, et al. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg 1991 Nov; 45 (5): 533-8
26. Bomford R, Stapleton M, Winsor S, et al. Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccine 1992; 10 (9): 572-7
27. Rogers WO, Malik A, Mellouk S, et al. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci USA 1992 Oct 1; 89 (19): 9176-80
28. Robson KJH, Hall JRS, Jennings MW, et al. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988 Sep; 335: 79-82
29. Wizel B, Rogers WO, Houghten RA, et al. Induction of murine cytotoxic T lymphocytes against Plasmodium falciparum sporozoite surface protein 2. Eur J Immunol 1994; 24: 1487-95
30. Wizel B, Houghten RA, Parker KC, et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med 1995 Nov; 182: 1435-45
31. Wizel B, Houghten R, Church P, et al. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J Immunol 1995; 155: 766-75
32. + T cell and IFN-γ-dependent elimination of infected hepatocytes. J Immunol 1996; 157: 4061-7
33. Khusmith S, Charoenvit Y, Kumar S, et al. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991 May 3; 252 (5006): 715-8
34. Guerin-Marchand C, Druilhe P, Galey B, et al. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 1987 Sep; 329: 164-7
35. Hill AVS, Allsopp CEM, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991 Aug 15; 352: 595-600
36. Hill AVS, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992 Dec; 360: 434-9
37. Fidock DA, Gras-Masse H, Lepers JP, et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 1994; 53: 190-204
38. Coppel RL, Favaloro JM, Crewther PE, et al. A blood stage antigen of Plasmodium falciparum shares determinants with the sporozoite coat protein. Proc Natl Acad Sci USA 1985 Aug; 82 (15): 5121-5
39. Hope I, Mackay M, Hyde J, et al. The gene for an exported antigen of the malaria parasite Plasmodium falciparum cloned and expressed in Escherichia coli. Nucleic Acids Res 1985; 13: 369-79
40. Gunther K, Tummler M, Hans-Henning A, et al. An exported protein of Plasmodium falciparum is synthesized as an integral membrane protein. Mol Biochem Parasitol 1991; 46: 149-58
41. Simmons D, Woollett G, Bergin-Cartwright M, et al. A malaria protein exported into a new compartment within the host erythrocyte. EMBO J 1987; 6 (2): 485-91
42. Sanchez GI, Rogers WO, Mellouk S, et al. Plasmodium falciparum: Exported Protein-1, a blood stage antigen, is expressed in liver stage parasites. Exp Parasitol 1994; 79: 59-62
43. + T cell-, interferon γ- and nitric oxide-dependent immunity. J Exp Med 1996 Apr; 183: 1739-46
44. Doolan DL, Hedstrom RC, Rogers WO, et al. Identification and characterization of the protective Hepatocyte Erythrocyte Protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum Exported Protein 1. J Biol Chem 1996 Jul; 271 (30): 17861-8
45. 19, a recombinant Plasmodium falciparum vaccine candidate, in adults. Trop Geogr Med 1992; 44: 9-14
46. Blackman MJ, Heidrich HG, Donachie S, et al. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 1990 July; 172: 379-82
47. Chang SP, Gibsoon HL, Lee-Ng CT, et al. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol Jul 1992; 149 (2): 548-55
48. Egan AF, Morris J, Barnish G, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa c-terminal fragment of the merozoite surface antigen, PfMSP-I. J Infect Dis March 1996; 173: 765-9
49. Chang SP, Case SE, Gosnell WL, et al. A recombinant baculovirus 42-kilodalton c-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 1996 Jan; 64 (1): 253-61
50. Ling IT, Ogun SA, Holder AA. Immunization against malaria with a recombinant protein. Parasite Immunol 1994; 16: 63-7
51. Daly TM, Long CA. A recombinant 15-kilodalton carboxy-terminal fragment of Plasmodium yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun 1993 Jun; 61 (6): 2462-7
52. Daly T, Long CA. Humoral response to a carboxy-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 1995; 155: 236-43
53. Burghaus PA, Wellde BT, Hall T, et al. Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect Immun 1996 Sep; 64 (9): 3614-9
54. Crisanti A, Müller HM, Hilbich C, et al. Epitopes recognized by human T cells map within the conserved part of the GP190 of P. falciparum. Science 1988 Jun; 240: 1324-6
55. Rzepczyk CM, Ramasamy R, Mutch DA, et al. Analysis of human T cell response to two Plasmodium falciparum merozoite surface antigens. Eur J Immunol 1989; 19: 1797-802
56. Camus D, Hadley TJ. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985 Nov; 230: 553-6
57. Sim KL, Orlandi PA, Haynes JD, et al. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol 1990 Nov; 111: 1877-84
58. Orlandi PA, Klotz FW, Haynes JD. A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(α2-3)Gal-Sequences of glycophorin A. J Cell Biol 1992 Feb; 116 (4): 901-9
59. Sim BKL, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 1994 Jun; 264: 1941-4
60. Daugherty JD, Murphy CI, Doros-Richert LA, et al. Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen-175 (EBA-175) polypeptides and their recognition by human antibodies. Infect Immun. In press
61. Perrin LH, Merkli B, Loche M, et al. Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages. J Exp Med 1984 Aug; 160: 441-51
62. Deans JA, Alderson T, Thomas AW, et al. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol 1982; 49: 2973-309
63. Thomas AW, Deans JA, Mitchell GH, et al. The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. Mol Biochem Parasitol 1984; 13: 187-99
64. Collins WE, Pye D, Crewther PE, et al. Protective immunity induced in Squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 1994; 51 (6): 711-9
65. Brown GV, Culvenor JG, Crewther PE, et al. Localization of the ring-infected erythrocyte surface antigen (RESA) of Plasmodium falciparum in merozoites and ring-infected erythrocytes. J Exp Med 1985 Aug; 162: 774-9
66. Berzins K, Perlmann H, Whalin B, et al. Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci USA 1986 Feb; 83: 1065-9
67. Collins WE, Anders RF, Pappaioanou M, et al. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 1986 Sep; 323: 259-62
68. Chirakalwasan N, Kamol-Ratanakul P, Lermaharit S, et al. A longitudinal study of seroreactivities to a major blood stage antigen (Pf155/RESA) of the malaria parasite Plasmodium falciparum in an endemic area of Thailand. Southeast Asian J Trop Med Public Health March 1994; 25 (1): 25-31
69. Al-Yaman F, Genton B, Anders R, et al. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and Spf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol 1995; 17: 493-501
70. Rooth I, Perlmann H, Anders B. Plasmodium falciparum reinfection in children from a holoendemic area in relation to seroreactivities against oligopeptides from different malaria antigens. Am J Trop Med Hyg 1991; 45 (3): 309-18
71. Banyal HS, Inselburg J. Isolation and characterization of parasite-inhibitory Plasmodium falciparum monoclonal antibodies. Am J Trop Med Hyg 1985; 34: 1055-64
72. Horii T, Bzik DJ, Inselburg J. Characterization of antigen-expressing Plasmodium falciparum cDNA clones that are reactive with parasite inhibitory antibodies. Mol Biochem Parastiol 1988; 30: 9-18
73. Bzik DJ, Li W, Horii T, et al. Amino acid sequence of the serine-repeat antigen (SERA) of Plasmodium falciparum determined from cloned cDNA. Mol Biochem Parastiol 1988; 30: 279-88
74. Higgins DG, McDonnell DJ. Malarial proteinase?' Nature 1989 Aug; 340: 604
75. Delplace P, Fortier B, Tronchin G, et al. Localization, biosynthesis, processing and isolation of a major 126 KDa antigen of the parasitophorous vacuole of Plasmodium falciparum. Mol Biochem Parasitol 1987; 23: 193-201
76. Inselburg J, Bzik DJ, Li W, et al. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum. Infect Immun 1991 Apr; 59 (4): 1247-50
77. Inselburg J, Bathurst IC, Kansopon J, et al. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity. Infect Immun 1993 May; 61 (5): 2041-7
78. Inselburg J, Bathurst, Kansopon J, et al. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infect Immun 1993 May; 61 (5): 2048-52
79. Lopez MC, Silva Y, Thomas MC, et al. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine. Vaccine 1994; 12 (7): 585-91
80. Patarroyo ME, Romero P, Torres ML, et al. Protective synthetic peptides against experimental Plasmodium falciparum-induced malaria. In: Brown F, Chanock R, Lerner R, editors. Vaccines 87. Cold Spring Harbor Laboratory, 1987: 117-24
81. Patarroyo ME, Romero P, Torres ML, et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987 Aug; 328: 629-32
82. Rodriguez R, Moreno A, Guzman F, et al. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am J Trop Med Hyg 1999; 43 (4): 339-54
83. Patarroyo ME, Amador R, Clavijo P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988 Mar; 332: 158-61
84. Ruebush TK, Campbell GH, Moreno A, et al. Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens. Am J Trop Med Hyg 1990; 43 (4): 355-66
85. Amador R, Moreno A, Valero V, et al. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine 1992; 10 (3): 179-84
86. Valero MV, Amador LR, Galindo C, et al. Vaccination with SPf66, a chemically synthesized vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993 Mar; 341: 705-10
87. Noya O, Berti YG, Alarcon de Noya B, et al. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 1994; 170: 396-402
88. Sempertegui F, Estrella B, Moscoso J, et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 1994; 12 (4): 337-42
89. Alonso PL, Smith T, Armstrong JRM, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994 Oct; 344: 1175-81
90. D'Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995 Aug; 346: 462-7
91. Nosten F, Luxemburger C, Kyle DE, et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 1996 Sept; 348: 701-7
92. Quakyi IA, Carter R, Rener J, et al. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J Immunol 1987 Dec; 139: 4213-7
93. Vermeulen AN, Meuwissen JHET. Sequential expression of antigens on sexual stages of P. falciparum accessible to transmission blocking antibodies in the mosquito. J Exp Med 1985; 162: 1460-76
94. Williamson KC, Keisler DB, Muratova O, et al. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol 1995; 75: 33-42
95. Graves PM, Carter R, Burkot TR, et al. Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera. Parasite Immunol 1988; 10: 209-18
96. Roeffen W, Mulde R, Teelen K, et al. Association between antiPfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon. Parasite Immunol 1996; 18: 103-9
97. Premawansa S, Gamage-Mendis A, Perera L, et al. Plasmodium falciparum malaria transmission-blocking immunity under conditions of low endemicity as in Sri Lanka. Parasite Immunol 1994; 16: 35-42
98. Feng Z, Hoffmann RN, Nussenzweig RS, et al. Pfs2400 can mediate antibody-dependent malaria transmission inhibition and may be the Plasmodium falciparum 11.1 gene product. J Exp Med 1993 Feb; 177: 273-81
99. Carter R, Graves PM, Creasy A, et al. Plasmodium falciparum: an abundant stage-specific protein expressed during early gametocyte development. Exp Parasitol 1989; 69: 140-9
100. Wizel B, Kumar N. Identification of a continuous and cross-reacting epitope for Plasmodium falciparum transmission-blocking immunity. Proc Natl Acad Sci USA 1991 Nov; 88: 9533-7
101. Kaslow DC, Quaki IA, Syin C, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988 May; 333: 74-6
102. Barr PJ, Green KM, Gibson HL, et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 1991 Nov; 174: 1203-8
103. Kaslow DC, Bathurst IC, Lensen T, et al. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 1994 Dec; 62 (12): 5576-80
104. Duffy P, Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 1997 Mar; 65 (3): 1109-13
105. Kaslow DC. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol 1997; 27 (2): 183-9
106. Lockyer MJ, Marsh K, Newbold CI. Wild isolates of Plasmodium falciparum show extensive polymorphism in T cell epitopes of the circumsporozoite protein. Mol Biochem Parasitol 1989 Dec; 37 (2): 275-80
107. Satchidanandam V, Zavala F, Moss B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol Biochem Parasitol 1991; 48: 89-100
108. Lanar DE, Tine JA, de Taisne C, et al. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun 1996 May; 64 (3): 1666-71
109. Ockenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998 Jun; 177 (6): 1664-73
110. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein (see comments). Science 1993 Mar 19; 259: 1745-9
111. Liu MA, Hilleman, MR, Kurth R. DNA vaccines: a new era in vaccinology. Ann NY Acad Sci 1995; 72: 1-294
112. Mor G, Klinman DM, Shapiro S, et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol 1995; 155: 2039-46
113. Sedegah M, Hedstrom R, Hobart P, et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1494 Oct; 91: 9866-70